Scientific Meeting Highlights from SITC

The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the 2023 ASH Annual Meeting. Below is a recap of highlighted research presented from Saturday, Dec. 9–Tuesday, Dec. 12, 2023 2023 Scientific Highlights Real-world safety and efficacy study of the BCMAxCD3 bispecific antibody teclistamab for relapsed or refractory multiple myeloma 91. Real-world safety and efficacy of teclistamab for patients with heavily pretreated relapsed-refractory multiple myeloma Danai Dima (Cleveland Clinic, Cleveland, OH, USA) ...
0 comments
2023 Scientific Highlights The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the 2023 ESMO Iummuno-Oncology Congress. Below is a recap of highlighted research presented from Wednesday, Dec. 6–Friday, Dec. 8, 2023 Results from GDFATHER-1/2, the first in-human trial of visugromab, a GDF-15 neutralizing antibody 118O. Definitive results for NSCLC and bladder cancer cohorts in the phase 2a trial of visugromab (CTL-002) in advanced/metastatic anti-PD/PD-L1 relapsed/refractory solid tumors (GDFATHER-trial) Ignacio ...
0 comments
Use of vaccines to boost CAR T efficacy and promote antigen spreading for long-term anti-tumor activity 286. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity Leyuan Ma (Children’s Hospital of Philadelphia, Philadelphia, PA, USA) reported results from a study of a synthetic vaccine (amph-vax) to enhance CAR T cell activity against solid tumors. Amph-vax consisted of a CAR-ligand linked to albumin-binding poly (ethylene glycol)-phospholipid and formulated with a cyclic-di-GMP (STING agonist). Fluorescently labeled amph-vax targeted lymph nodes and associated with antigen presenting cells ...
0 comments
Correlation of tertiary lymphoid structures with survival benefits in patients treated with first line atezolizumab for metastatic lung cancer 606. IMpower110: Tertiary lymphoid structures (TLS) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with first-line atezolizumab Barzin Nabet (Genentech, South San Francisco, CA, USA) presented an analysis to evaluate the clinical utility of tertiary lymphoid structures (TLS) as a biomarker associated with clinical benefits from immunotherapy in patients with untreated metastatic non-small cell lung cancer (mNSCLC). Prior studies have indicated that B-cell and plasma-cell ...
0 comments
Neutrophils are important for the destruction of heterogenous tumors in mouse models of melanoma 878. T cell immunotherapies recruit and activate neutrophils to eliminate tumor antigen escape variants Daniel Hirschhorn (Weill Cornell Medical and Graduate Schools, New York, NY, USA) presented a study investigating the mechanisms of immune-mediated destruction of heterogeneous tumors that contain antigen-loss variants. Selective pressures of the immune system create heterogeneity and antigen-loss variants within tumors, and this heterogeneity often leads to resistance to T cell-targeted immunotherapies. Mouse models of Trp1+ B16 melanoma ...
0 comments
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the 2023 ESMO Congress. Below is a recap of highlighted research presented from Friday, October 20 through Tuesday, October 24, 2023. Exploring the clinical effectiveness of perioperative immune checkpoint inhibitors in combination with chemotherapy for advanced gastric and gastroesophageal junction cancer LBA74. Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study Kohei Shitara ...
0 comments
Lisocabtagene maraleucel for relapsed or refractory chronic lymphocytic leukemia and small lymphocytic leukemia 7501. Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of TRANSCEND CLL 004. Tanya Siddiqi (City of Hope National Medical Center, Duarte, CA) presented efficacy and safety data from the primary efficacy analysis set (n=87) of TRANSCEND CLL 004, which examined lisocabtagene maraleucel (liso-cel), a CD19-directed CAR T cell product in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The Primary ...
0 comments
Nivolumab-based neoadjuvant chemoimmunotherapy followed by response-adapted chemoradiation therapy is associated with deep responses and favorable survival for HNSCC 6007. Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial. Ari Rosenberg (University of Chicago, Chicago, IL – SITC Member ) reported results from the phase II DEPEND trial of neoadjuvant chemoimmunotherapy followed by chemoradiation therapy (CRT) for advanced HPV-negative head and neck squamous cell carcinoma (HNSCC). ...
0 comments
Blockade of immune modulator GDF-15 combined with nivolumab for advanced solid tumors 2501. Initial results from the phase 2A trial of visugromab (CTL-002) + nivolumab in advanced/metastatic anti-PD1/-L1 relapsed/refractory solid tumors (The GDFATHER-TRIAL). Ignacio Melero Bermejo (Clinica Universitaria de Navarra, Pamplona, Spain) reported initial results from the GDFATHER-TRIAL, a phase IIa trial of visugromab (CTL-002) combined with nivolumab for advanced or metastatic solid tumors. CTL0-002 blocks GDF-15, an immune modulating molecule that inhibits the infiltration of immune cells into the tumor microenvironment and limits the efficacy ...
0 comments
Perioperative pembrolizumab is associated with survival benefits for early-stage NSCLC LBA100. KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC. Heather A. Wakelee (Stanford University, Stanford, CA) presented an interim analysis of KEYNOTE-671, a randomized, double-blind phase III trial investigating a perioperative approach that includes immune checkpoint inhibition before and after surgical resection of stage II, IIIA or IIIB(N2) non-small cell lung cancer (NSCLC) per AJCC v8. Patients were ...
0 comments
Dual-target natural killer cell engager for treatment of acute myeloid leukemia 7005. A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia . Anthony Selwyn Stein (City of Hope National Medical Center, Duarte, CA) presented preliminary safety and efficacy data from phase I/II trial of SAR443579 (SAR’579), a trifunctional natural killer (NK) cell engager for relapsed or refractory (r/r) acute myeloid leukemia (AML). SAR’579 targets CD123, which is widely expressed in hematologic malignancies, and co-engages NKp46 and Cd16a ...
0 comments
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the 2023 ASGCT Annual Meeting. Below is a recap of highlighted research presented from Tuesday, May 16 through Saturday, May 20, 2023. Scientific Highlights CAR signaling domains affect the dynamics of CAR T cell anti-cancer activity 89: CAR Signaling Drives Distinct Immunological Synapse Dynamics That Influence the T Cell Behavior in Killing Cancer Ahmed Z. Gad (Baylor College of Medicine, Houston, TX) presented a study comparing the dynamics of CD28 and 41BB signaling domains at CAR immunological ...
0 comments
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the 2023 AACR Annual Meeting. Below is a recap of highlighted research presented from Friday, April 14 through Wednesday, April 19, 2023. Scientific Highlights A PERSONALIZED MRNA CANCER VACCINE COMBINED WITH IMMUNE CHECKPOINT INHIBITORS FOR MELANOMA CT001. A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201/Keynote-942 trial Jeffrey ...
0 comments
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ASH Annual Meeting 2022. Below is a recap of highlighted research presented from Saturday, Dec. 10 through Tuesday, Dec. 13, 2022. Scientific Highlights The MagnetisMM-1 trial: A BCMA-targeting bispecific T cell engager for relapsed or refractory multiple myeloma Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma Noopur Raje ( Massachusetts General Hospital ...
0 comments
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ESMO Immuno-Oncology Congress 2022. Below is a recap of highlighted research presented from Wednesday, Dec. 7 through Friday, Dec. 9, 2022. Scientific Highlights Combining a small molecule inhibitor of KRAS G12C with immune checkpoint blockade for first-line treatment of NSCLC LBA4. Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation Pasi Jänne (Harvard University, ...
0 comments
Scientific Highlights for Saturday, Nov. 12, 2022 ELUCIDATING THE DEVELOPMENT AND FUNCTION OF CANCER-ASSOCIATED FIBROBLASTS 1450 TGF beta dependent LRRC15+ myofibroblasts dictate the tumor fibroblast setpoint to promote cancer immunotherapy resistance Akshay Krishnamurty (Genentech, United States) presented results from a study to identify the origin and function of LRRC15+ cancer associated fibroblasts (CAFs). LRRC15+ CAFs support tumor growth through the expression immunosuppressive and extracellular matrix genes. Previous studies have shown that high expression of the LRRC15+ CAF gene signature corresponds to decreased survival ...
0 comments
Scientific Highlights for Friday, Nov. 11, 2022 CD8+ FOXP3+ CELLS PREDICT RESPONSE TO IMMUNOTHERAPY FOR NSCLC CD8+FoxP3+ cells represent early, effector T-cells and predict outcomes in patients with resectable non-small cell lung carcinoma (NSCLC) receiving neoadjuvant anti-PD-1-based therapy Tricia Cottrell (Queen’s University, Canada) presented a study to identify biomarkers of therapeutic response in patients with non-small cell lung carcinoma (NSCLC) receiving neoadjuvant anti-PD-1 therapy. Pre-treatment tumor specimens from patients in the clinical trial of neoadjuvant nivolumab +/- ipilimumab were stained with markers ...
0 comments
Scientific Highlights for Thursday, Nov. 10, 2022 TCR T CELL THERAPY TARGETING NEOANTIGENS IN SOLID TUMORS A Phase I study of personalized adoptive TCR T cell therapy in patients with solid tumors: safety, efficacy, and T cell trafficking to tumors of non-virally gene edited T cells. Stephanie Mandl (PACT Pharma, United States) presented on a Phase I study of NeoTCR-P1, a personalized autologous T cell therapy for treatment of solid tumors. Neoantigen-specific T cell receptors (neoTCRs) were isolated and cloned from patients’ circulating CD8 T cells and inserted into an autologous cell product by non-viral genome engineering ...
0 comments
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ESMO Congress 2022. Below is a recap of highlighted research presented from Friday, Sept. 9 through Tuesday, Sept. 13, 2022. Scientific Highlights Safety and efficacy of preoperative treatment of NSCLC with nivolumab and relatlimab LBA37. A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung) Martin H. Schuler (University Hospital Essen, Germany) presented results from ...
0 comments
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the Keystone Symposium on Cancer Neoantigens, Vaccines, and Viruses. Below is a recap of highlighted research presented from Wednesday, June 8 through Sunday, June 12, 2022. Scientific Highlights Identifying T-cell Targets for TAP-Impaired Tumors Shared Neoantigens as T-Cell Targets for TAP-Impaired Tumors (Revised as of 10:15 a.m. CDT, 6/15/2022) Sjoerd H. van der Burg (Leiden University Medical Center) presented efforts focused on exploiting a divergent mode of antigen presentation ...
0 comments